Abstract

Although treatments are currently established, heart failure (HF) remains the leading cause of hospitalization and mortality worldwide. Therefore, new therapeutic targets are needed to improve the prognosis of patients with heart failure, especially those with preserved ejection fraction. In recent years, many clinical studies have shown that sodium glucose cotransporter-2inhibitors can significantly reduce the hospitalization rate and mortality of heart failure. It is expected to become a new method for the treatment of heart failure, and this effect also exists in non-diabetic heart failure patients. But its potential mechanisms of action are not fully understood yet and needs further exploration. This article reviews the effects and the potential mechanisms of SGLT2 inhibitors in heart failure.

Keywords: SGLT2 inhibitors; Heart failure